Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBIT (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EBIT for 11 consecutive years, with -$29.9 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 21.85% to -$29.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$131.8 million through Dec 2025, down 58.3% year-over-year, with the annual reading at -$131.8 million for FY2025, 58.3% down from the prior year.
  • EBIT hit -$29.9 million in Q4 2025 for Voyager Therapeutics, up from -$30.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $122.9 million in Q1 2023 to a low of -$39.9 million in Q4 2023.
  • Historically, EBIT has averaged -$15.6 million across 5 years, with a median of -$25.3 million in 2021.
  • Biggest five-year swings in EBIT: plummeted 530.78% in 2022 and later surged 675.57% in 2023.
  • Year by year, EBIT stood at $5.7 million in 2021, then tumbled by 530.78% to -$24.6 million in 2022, then plummeted by 62.3% to -$39.9 million in 2023, then grew by 3.93% to -$38.3 million in 2024, then increased by 21.85% to -$29.9 million in 2025.
  • Business Quant data shows EBIT for VYGR at -$29.9 million in Q4 2025, -$30.6 million in Q3 2025, and -$36.6 million in Q2 2025.